Psoriatic Arthritis (PsA) Treatment Market

Psoriatic Arthritis (PsA) Treatment Market Outlook for 2024 to 2034

The global Psoriatic Arthritis (PsA) Treatment Market is set to acquire a value of USD 11,973.7 million in 2024. By 2034, the value of the psoriatic arthritis (PsA) treatment market is slated to shoot upwards of USD 25,375.6 million. As such, the sector is anticipated to progress at a CAGR of 7.8%.

The need for psoriatic arthritis (PsA) treatment arises as a result of psoriasis affecting a significant number of people globally. It is claimed that about 125 million people worldwide suffer from the disease. As the number of people affected by the disorder continues to climb, the need for related treatment increases too.

Psoriasis majorly affects people in the 50-60 age range, being the pinnacle age where the symptoms first start showing. As the population of the world is aging rapidly, more people with psoriatic arthritis are populating hospitals. As such, the patient pool for the treatment is getting wider.

It's not just the geriatric population that comprises the patient pool, 20 to 30 is another prominent age when the symptoms of psoriasis start showing. Thus, the psoriatic arthritis (PsA) treatment market is advancing through multiple avenues.

Psoriatic arthritis can lead to conditions that drive people to seek treatment fast. Conditions like morning stiffness, nail pitting, flaky scalp, and more affect patients majorly. Thus, a rising number of people are turning to the treatment.

There are some downsides to the industry, however. The high cost of certain treatments deters patients from taking its help. The side effects of medication for psoriatic arthritis, which may include infection, lung inflammation, hair loss, and more, also prove to be a negative point.

Online consulting and treatment options also help the sector move into the modern digital world. As such, the easy availability of medicine and treatment options is leading to demand being established at a faster rate.

Attributes	Description
Established Value for 2024	USD 11,973.7 million
Projected Value for 2034	USD 25,375.6 million
Value-based CAGR from 2024 to 2034	7.8%

Key Industry Highlights

Variety of Treatment Options Make the Psoriatic Arthritis (PsA) Treatment Market’s Case Easier

The wide variety of treatment options available boosts the industry. These treatment options range from over-the-counter drugs to extensive surgeries. Some of the treatment options available include biologics, steroid injections, and joint replacement surgeries.

Regulatory bodies like the Food and Drug Administration (FDA) approving new treatments at a rapid rate also help the ascent of the sector. Some medications that have received approval from the FDA in recent times include Guselkumab and Risankizumab-rzaa.

Constant Clinical Trials Keep the Industry from Becoming Stagnant

As new drugs get approved at a rapid rate, pharma companies and health institutions are looking to refine treatment further. Trails for starting new types of medication are common.

Pharma sector players are investing significant amounts of money in these trials. Government grants are also helping in this venture. Some of the promising drugs under trial currently are Bimekizumab and Netakimab. Thus, the industry’s prospects remain fresh.

Treatment Options Going Online Helps Sales to Flourish

Digital pharmacies and telehealth are set to play a significant part in the industry’s development. With the help of online pharmacies, suppliers are making the medications available at a moment’s notice, making patients more inclined towards the treatment.

2019 to 2023 Global Psoriatic Arthritis (PsA) Treatment Sales Analysis Compared to Demand Forecasts for 2024 to 2034

The psoriatic arthritis (PsA) treatment market advanced at a rate of 7.4% for the period between 2019 to 2023. While the 2019 value was tipped to be USD 7,816.3 million, the 2023 value jumped to USD 11,153.9 million.

The pandemic served to divert attention away from disorders other than Covid-19. Clinical trials too were concentrated majorly on finding vaccines and treatments for the disease. As such, the treatment’s growth rate was negatively affected.

However, the industry grew in other ways in the historical period. The rise of telehealth, digital pharmacies, and online consultations gave a new look to the market.

The sector is set to advance at a higher rate in the forecast period as compared to the historical period. Much of the success of the treatment going forward is predicated on the role of regulatory bodies.

As more treatments get approved, the industry is set to flourish. If the treatments get approved as quickly as they have been historically, the industry’s progress is set to be swift.

Alternative treatments of psoriatic arthritis are also set to gain more prominence in the coming decade. For example, light therapy and acupuncture are treatments that are becoming more popular.

Category-wise Outlook

Biologics are the top type of drugs administered for the disease. Medications for the disorder are overwhelmingly taken through the injectable mode.

Positive Recent Results of Biologics Help Them Climb to the Top in the Drug Type Segment

Biologics are penned in to take up 57.2% of the market share in 2024.

Disease-modifying antirheumatic drugs (DMARDs) have been the go-to treatment options prescribed by doctors. DMARDs like methotrexate have been relied upon by doctors historically. However, biological versions of DMARDs are coming to the fore.

Biologics have proven themselves to be effective in combatting inflammation, swelling, and other conditions caused by psoriatic arthritis. The treatment type is also reported to cause fewer side effects as compared to standard drugs.

The adoption of biologics is also helped by regulatory bodies approving their use at a fast rate. The approval of biologics like adalimumab (Humira) and ixekizumab (Taltz) helps the segment emerge on top in the drug type category.

Attributes	Details
Top Drug Type	Biologics
Industry Share (2024)	57.2%

Injectable Drugs Rule the Roost When it Comes to Route of Administration

For 2024, injectable drugs are predicted to remain at the top, with a share of 84.9%.

Injectable drugs have established themselves as the preferred treatment option by both doctors and patients. Injectable versions of the drugs are generally reputed to act faster in treatment as compared to oral drugs. Thus, their dominance continues in the route of administration segment.

Attributes	Details
Top Route of Administration	Injectable
Industry Share (2024)	84.9%

Country-Wise Analysis

The drive to make drugs and medications available in rural areas broadens the market’s scope in the Asia Pacific. The aging population in North America necessitates the recourse of treatment in the region.

Countries	CAGR (2024 to 2034)
Japan	7%
China	8.4%
United States	7.5%
South Africa	6.6%
United Kingdom	7.6%
Canada	7%
Italy	6.8%
Germany	7.8%
France	7.3%
Spain	6.5%
India	8.9%
Australia	7.9%

Rapidly Aging Population in the United States Contributing to Industry Growth

The United States is set to witness the industry progress at a CAGR of 7.5% over the forecast period. The population of the United States is getting older at a concerning rate. It is estimated that by 2040, one in five Americans will be over the age of 65.

Thus, the conditions are right for the psoriatic arthritis (PsA) treatment market to flourish in the country.

Health Schemes Targeting Psoriasis Awareness Aid Industry’s Cause in India

The sector is set to expand at a CAGR of 8.9% in India, making the country lucrative for players. National health schemes by the government target the raising of awareness relating to psoriasis aid the sector’s growth in India.

Foreign pharma companies like Eli Lilly are making efforts to introduce new drugs and modernize the treatment procedure in India.

Approval of Novel Drugs Helps Industry’s Growth in the United Kingdom

The United Kingdom is set to see market growth happen at a CAGR of 7.6% over the coming decade.

The market in the United Kingdom is developing as a result of new drugs being developed and approved at a satisfactory pace. For example, in 2022, Rinvoq (upadacitinib), manufactured by AbbVie received clearance from the United Kingdom National Institute for Health and Care Excellence (NICE) for the treatment of adult patients with psoriatic arthritis.

Competitive Landscape in the Psoriatic Arthritis (PsA) Treatment Market

The development of new drugs remains a priority for players. In addition, collaborative strategies are also part of the vision. Partnerships with public bodies are sought to raise awareness about the disease.

The need for developing novel drug options is evident when looking at an industry giant like Pfizer Inc.

The company also partners with other healthcare sector players for the development of new drugs. Johnson and Johnson also concentrate on new drug development, investing significant amounts into trials.

Recent Developments in the Psoriatic Arthritis (PsA) Treatment Market

In September 2023, Wellmin Health, in collaboration with the non-profit organization Versus Arthritis, launched the Pathway platform. It is a program developed to help patients with arthritis, including psoriatic arthritis.

In February 2024, Biocon Biologics announced that it had reached an agreement with Janssen Biotech Inc. and Johnson & Johnson to commercialize the drug Bmab 1200.

Key Companies in the Psoriatic Arthritis (PsA) Treatment Market

Key companies in the industry include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, UCB S.A., Eli Lilly & Co, Novartis AG, Celgene Corporation, and AstraZeneca PLC.

Key Segments of Psoriatic Arthritis (PsA) Treatment Market

By Drug Type:

Based on the drug type, the psoriatic arthritis (PsA) treatment market can be segmented into the following segments: non-steroidal anti-inflammatory drugs, disease modifying anti-rheumatic drugs, and biologics.

Disease-modifying anti-rheumatic drugs can be further separated into corticosteroids, antimalarial, methotrexate, and others. On the other hand, biologics can be bifurcated into TNF inhibitors and interleukin inhibitors.

By Route of Administration:

Based on the route of administration, the psoriatic arthritis (PsA) treatment market can be bifurcated into the following segments: injectable and oral.

By Distribution Channel:

Based on the distribution channel, the psoriatic arthritis (psa) treatment market can be segmented into the following segments: hospital pharmacies, retail pharmacies, and mail-order pharmacies.

By Region:

The sector has been analyzed with the following regions covered: North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East and Africa.